# The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

> **NCT00381381** · PHASE4 · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 199 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Donepezil

## Key facts

- **NCT ID:** NCT00381381
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-31
- **Primary completion:** 2008-08-31
- **Final completion:** 2008-12-31
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381381, "The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00381381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*